NDC 0078-0641 Signifor Lar

Pasireotide

NDC Product Code 0078-0641

NDC CODE: 0078-0641

Proprietary Name: Signifor Lar What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Pasireotide What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • Pasireotide is used to treat a certain condition (acromegaly) that occurs when the body makes too much of a certain natural substance called growth hormone. Treating acromegaly helps reduce the risk of serious problems such as diabetes and heart disease. Pasireotide works by decreasing the amount of growth hormone made in the body. Pasireotide is also used to treat a certain condition (Cushing's disease) when surgery has not been fully successful or cannot be used to correct the condition. Cushing's disease occurs when the body makes too much of a certain hormone called cortisol. Having too much cortisol in the body may lead to high blood pressure, high blood sugar, and other problems. Pasireotide works by decreasing the amount of cortisol made in the body.

NDC Code Structure

  • 0078 - Novartis Pharmaceuticals Corporation

NDC 0078-0641-81

Package Description: 1 KIT in 1 KIT * 6 mL in 1 VIAL, SINGLE-USE (0078-0762-61) * 2 mL in 1 SYRINGE

NDC Product Information

Signifor Lar with NDC 0078-0641 is a a human prescription drug product labeled by Novartis Pharmaceuticals Corporation. The generic name of Signifor Lar is pasireotide. The product's dosage form is kit and is administered via form. The RxNorm Crosswalk for this NDC code indicates multiple RxCUI concepts are associated to this product: 1597596, 1597599, 1597601, 1597603 and 1597820.

Dosage Form: Kit - A packaged collection of related material.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 63000 MW) (UNII: QD923V64H3)
  • POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) (UNII: WE369X5600)
  • MANNITOL (UNII: 3OWL53L36A)
  • CARBOXYMETHYLCELLULOSE SODIUM (UNII: K679OBS311)
  • POLOXAMER 188 (UNII: LQA7B6G8JG)
  • WATER (UNII: 059QF0KO0R)
  • POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 63000 MW) (UNII: QD923V64H3)
  • POLY(DL-LACTIC-CO-GLYCOLIC ACID), (50:50; 12000 MW) (UNII: WE369X5600)
  • MANNITOL (UNII: 3OWL53L36A)
  • CARBOXYMETHYLCELLULOSE SODIUM (UNII: K679OBS311)
  • POLOXAMER 188 (UNII: LQA7B6G8JG)
  • WATER (UNII: 059QF0KO0R)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Novartis Pharmaceuticals Corporation
Labeler Code: 0078
FDA Application Number: NDA203255 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 12-15-2014 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

End Marketing Date: 09-30-2022 What is the End Marketing Date?
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Signifor Lar Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1.1     Acromegaly

SIGNIFOR LAR is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

1.2     Cushing’S Disease

SIGNIFOR LAR is indicated for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

2.1     Recommended Baseline Evaluations Prior To Initiation Of Signifor Lar

  • Prior to the initiation of SIGNIFOR LAR, it is recommended that patients have the following baseline evaluations:Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) [see Warnings and Precautions (5.1)]Liver tests [see Warnings and Precautions (5.3)]Electrocardiogram (ECG), serum potassium and serum magnesium levels [see Warnings and Precautions (5.2)]Patients with poorly controlled diabetes mellitus, who have inadequate glucose control, should have anti-diabetic therapy optimized prior to starting SIGNIFOR LAR [see Warnings and Precautions (5.1)].

2.2     Important Administration Instructions

SIGNIFOR LAR must be reconstituted by a trained healthcare professional immediately before use. Illustrations on reconstitution are found in Instructions for Use [see Dosage and Administration (2.6)].SIGNIFOR LAR must be inspected visually before use. The suspension should appear free of foreign particulates and should be homogeneous after mixing.SIGNIFOR LAR must be administered by a trained healthcare professional only by intramuscular injection in the right or left gluteus immediately after reconstitution. SIGNIFOR LAR must never be administered intravenously.

2.3     Recommended Initial Dose

AcromegalyThe recommended initial dose of SIGNIFOR LAR for the treatment of acromegaly is 40 mg administered by intramuscular injection once every 4 weeks (every 28 days) [see Dosage and Administration (2.6)].Cushing’s DiseaseThe recommended initial dose of SIGNIFOR LAR for the treatment of Cushing’s disease is 10 mg administered by intramuscular injection once every 4 weeks (every 28 days) [see Dosage and Administration (2.6)].

2.4     Dose Adjustment And Monitoring

AcromegalyThe dose may be increased to a maximum of 60 mg for patients who have not normalized growth hormone (GH) and/or age and sex adjusted insulin-like growth factor-1 (IGF-1) levels after 3 months of treatment with SIGNIFOR LAR at 40 mg and who tolerate this dose.Management of SIGNIFOR LAR-related adverse reactions or over-response to treatment (age and sex adjusted IGF-1 less than the lower limit of normal) may require dose reduction. The dose may be decreased, either temporarily or permanently, by 20 mg decrements [see Warnings and Precautions (5)].Cushing’s DiseaseFollowing 4 months of treatment with the initial dose of 10 mg once every 28 days, the dose may be increased for patients who have not normalized 24-hour urinary free cortisol (UFC) and who tolerate this dose, up to a maximum dose of 40 mg once every 28 days.Management of suspected adverse reactions or over-response to treatment (e.g., cortisol levels less than the lower limit of the normal range or in the low part of the normal range in patients with symptoms suggestive of adrenal insufficiency) may require dose reduction to the previous tolerated dose, dose interruption, or drug discontinuation of SIGNIFOR LAR. For patients treated with 10 mg once every 28 days, the dose may be either interrupted or discontinued [see Warnings and Precautions (5)].

2.5     Dose In Patients With Hepatic Impairment

  • For patients with moderately impaired hepatic function (Child-Pugh B) [see Use in Specific Populations (8.6)]:Acromegaly: The recommended initial dose for acromegaly patients with moderately impaired hepatic function is 20 mg once every 4 weeks and the maximum recommended dose is 40 mg once every 4 weeks.Cushing’s Disease: The recommended initial dose for Cushing’s disease patients with moderately impaired hepatic function is 10 mg once every 4 weeks and the maximum recommended dose is 20 mg once every 4 weeks.Avoid use in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.6)].

2.6     Reconstitution And Intramuscular Injection Instructions

After reconstitution of the SIGNIFOR LAR vial with the provided 2 mL diluent, the intramuscular injectable suspension will have a final concentration of:Strength per VialFinal Concentration When Reconstituted
(total product strength per total volume)
Final Concentration When Reconstituted (per mL)10 mg10 mg/2 mL
5 mg/mL
20 mg20 mg/2 mL
10 mg/mL
30 mg30 mg/2 mL
15 mg/mL
40 mg40 mg/2 mL
20 mg/mL
60 mg60 mg/2 mL
30 mg/mL
The entire contents of the reconstituted solution should be administered immediately.PAY PARTICULAR ATTENTION:There are 2 critical steps in the reconstitution of SIGNIFOR LAR. Not following these 2 steps could result in failure to deliver the drug appropriately.1) The injection kit must reach room temperature (see Step 1 in Instructions for Use). Remove the SIGNIFOR LAR injection kit from refrigerated storage and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.2) After adding the diluent solution, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed (see Step 4 in Instructions for Use).The following items are included in the injection kit: a) One vial containing SIGNIFOR LAR powder b) One prefilled syringe containing the diluent solution for reconstitutionc) One vial adapter for drug product reconstitutiond) One safety injection needle (20G x 1.5”)Figure 1. Items Included in Injection KitSIGNIFOR LAR suspension must only be reconstituted immediately before administration.
Follow the directions in the Instructions for Use to ensure proper reconstitution of SIGNIFOR LAR before intramuscular injection.
SIGNIFOR LAR should only be administered by a trained healthcare professional.Instructions for UseStep 1Remove the SIGNIFOR LAR for injectable suspension kit from refrigerated storage. PAY PARTICULAR ATTENTION: It is essential to start the reconstitution process only after the injection kit has reached room temperature. Let the kit stand at room temperature for at least 30 minutes before starting reconstitution, but not more than 24 hours.Note: The kit can be re-refrigerated if needed.Step 2Remove the plastic cap from the vial and clean the rubber stopper with an alcohol wipe.Remove the lid film of the vial adapter packaging, but do NOT remove the vial adapter from its packaging.Holding the vial adapter packaging, position the vial adapter on top of the vial and push it fully down so that it snaps in place. You will hear an audible “click” when the vial adapter snaps in place.Lift the packaging off the vial adapter with a vertical movement.Step 3Remove the cap from the syringe prefilled with diluent solution and screw the syringe onto the vial adapter.Slowly push the plunger all the way down to transfer all the diluent solution in the vial.Step 4ATTENTION: Keep the plunger pressed and shake the vial moderately in a horizontal direction for a minimum of 30 seconds so that the powder is completely suspended. Repeat moderate shaking for another 30 seconds if the powder is not completely suspended.Step 5Turn the syringe and vial upside down, slowly pull the plunger back and draw the entire content from the vial into the syringe.Unscrew the syringe from the vial adapter.Step 6Screw the safety injection needle onto the syringe.Pull the protective cover straight off the needle.To avoid sedimentation and maintain a uniform suspension, you may gently shake the syringe.Gently tap the syringe to remove any visible bubbles and expel them from the syringe.The reconstituted SIGNIFOR LAR is now ready for immediate administration.Step 7SIGNIFOR LAR must only be given by intramuscular injection and NEVER intravenously.Prepare the injection site by wiping with an alcohol wipe.Insert the needle fully into the left or right gluteus at a 90° angle to the skin.Slowly pull back the plunger to check that no blood vessel has been penetrated (reposition if a blood vessel has been penetrated).Slowly depress the plunger until the syringe is empty. Withdraw the needle from the injection site and activate the safety guard (as shown in Step 8).Step 8Activate the safety guard over the needle using 1 of the 2 methods shown:• either press the hinged section of the safety guard down onto a hard surface (Figure A),• or push the hinge forward with your finger (Figure B).An audible “click” will confirm proper activation of the safety guard.Dispose of syringe immediately in a sharps container.
Any unused product or waste material should be disposed of in accordance with local requirements.

2.7     Missed Dose

If a dose is missed and the patient returns prior to the next scheduled dose, a dose may be given up to but no later than 14 days prior to the next dose.

3     Dosage Forms And Strengths

SIGNIFOR LAR for injectable suspension: 10 mg, 20 mg, 30 mg, 40 mg, or 60 mg of slightly yellow to yellow powder in a vial and 2 mL diluent.

4     Contraindications

None.

5.1     Hyperglycemia And Diabetes

SIGNIFOR LAR can cause increases in blood glucose levels which are sometimes severe. In the study of patients with acromegaly, 5 patients naïve to drug therapy exposed to SIGNIFOR LAR (2 of whom were normoglycemic at baseline) were hospitalized for blood glucose in the range of 359-506 mg/dL and none in the active comparator group. Two additional patients who had received active comparator in the main trial and were switched to SIGNIFOR LAR in the extension trial, were hospitalized for elevated glucose levels while on SIGNIFOR LAR treatment during the extension; one of those patients developed diabetic ketoacidosis. In the Cushing’s disease study, 2 patients were hospitalized for elevated blood glucose. Patients with poor baseline glycemic control are at higher risk of developing severe hyperglycemia [see Dosage and Administration (2.1)].In clinical studies for acromegaly and Cushing’s disease, treatment with SIGNIFOR LAR caused an increase in the incidence of diabetes and prediabetes. A majority of patients, including those with normal glucose tolerance, prediabetes and diabetes, experienced increased glucose levels within the first 3 months of treatment with SIGNIFOR LAR [see Adverse Reactions (6.1)]. In the drug-naïve acromegaly study, the prevalence of diabetes increased from 30% at baseline to 60% at Month 12. In the study evaluating acromegaly patients previously treated with somatostatin analogs, the prevalence of diabetes increased from 71% at baseline to 87% at Month 6 in patients treated with SIGNIFOR LAR 40 mg, and from 60% to 84% in patients treated with SIGNIFOR LAR 60 mg. In the Cushing’s disease study, the prevalence of diabetes increased from 40% at baseline to 56% at Month 12.Fasting plasma glucose and HbA1c should be assessed prior to starting treatment with SIGNIFOR LAR. In patients with poorly controlled diabetes mellitus, anti-diabetic treatment should be optimized per standard of care before SIGNIFOR LAR treatment is started. Blood glucose monitoring should be done weekly for the first 3 months after initiating SIGNIFOR LAR and the first 4- to 6 weeks after dose increases. Periodic monitoring should continue thereafter, as clinically appropriate.Patients who develop significant hyperglycemia on SIGNIFOR LAR may require initiation of anti-diabetic therapy or adjustment in their current anti-diabetic therapy per standard of care. The optimal treatment for the management of SIGNIFOR LAR-induced hyperglycemia is not known. If hyperglycemia cannot be controlled despite medical management, the dose of SIGNIFOR LAR should be reduced or SIGNIFOR LAR should be discontinued.After treatment discontinuation, fasting plasma glucose and hemoglobin A1c should be assessed if indicated. Patients on anti-diabetic therapy discontinuing SIGNIFOR LAR may require more frequent blood glucose monitoring and anti-diabetic drug therapy dose adjustment to mitigate the risk of hypoglycemia.

5.2     Bradycardia And Qt Prolongation

  • BradycardiaBradycardia has been reported with the use of SIGNIFOR LAR [see Adverse Reactions (6.1)]. Patients with cardiac disease and/or risk factors for bradycardia, such as history of clinically significant bradycardia, high-grade heart block, or concomitant use of drugs associated with bradycardia, should be monitored. Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment.
  • QT ProlongationIn cardiac electrophysiology studies (i.e., thorough QT studies) with pasireotide via subcutaneous route, QT prolongation occurred at therapeutic and supra-therapeutic doses [see Clinical Pharmacology (12.2)].
  • In the clinical studies, a corrected QT interval (i.e., QTcF) of greater than 480 ms was reported in 6 patients and an increase in the QTcF from baseline of greater than 60 ms was reported for seven patients on SIGNIFOR LAR. No patient on SIGNIFOR LAR had a QTcF value of greater than 500 ms [see Adverse Reactions (6.1), Clinical Pharmacology (12.2)].SIGNIFOR LAR should be used with caution in patients who are at significant risk of developing prolongation of the QT interval, such as those listed below:with congenital long QT prolongationwith uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardiaon anti-arrhythmic therapy or other substances that are known to lead to QT prolongationwith hypokalemia and/or hypomagnesemiaA baseline ECG is recommended prior to initiating therapy with SIGNIFOR LAR. Monitoring for an effect on the QT interval at the time of maximum drug concentration (21 days after injection) should be obtained in patients at risk. Hypokalemia or hypomagnesemia must be corrected prior to initiating SIGNIFOR LAR and should be monitored periodically during therapy.

5.3     Liver Test Elevations

Increases in liver enzymes have been observed with SIGNIFOR LAR. In all Phase 3 acromegaly studies and across all doses, alanine aminostranferase (ALT) or aspartate aminotransferase (AST) elevations greater than 3 times the upper limit of normal (ULN) were observed in 4% of acromegaly patients and ALT or AST elevations greater than 5 times the ULN were observed in 1% of acromegaly patients treated with SIGNIFOR LAR.In the Phase 3 Cushing’s disease study and across all doses, ALT or AST elevations greater than 3 times the ULN were observed in 14% of Cushing’s disease patients and ALT or AST elevations greater than 5 times the ULN were observed in 5% of Cushing’s disease patients treated with SIGNIFOR LAR.Assessment of liver function is recommended prior to treatment with SIGNIFOR LAR , and after the first 2- to 3 weeks, then monthly for 3 months. Thereafter, liver function should be monitored as clinically indicated. Patients who develop increased transaminase levels, should be monitored until values return to pre-treatment levels. Treatment with SIGNIFOR LAR should be discontinued if signs or symptoms suggestive of clinically significant liver impairment develop. Following discontinuation of treatment with SIGNIFOR LAR, patients should be monitored until resolution. Treatment should not be restarted, if the liver function abnormalities are suspected to be related to SIGNIFOR LAR.

5.4     Cholelithiasis And Complications Of Cholelithiasis

Cholelithiasis was reported in 33% of drug-naïve and 10% of inadequately controlled (40 mg dose) acromegaly patients treated with SIGNIFOR LAR in clinical trials [see Adverse Reactions (6)]. Cholelithiasis was reported in 33% of Cushing’s disease patients treated with SIGNIFOR LAR. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis or cholangitis and requiring cholecystectomy in patients taking SIGNIFOR LAR. Patients should be monitored periodically. If complications of cholelithiasis are suspected, discontinue SIGNIFOR LAR and treat appropriately.

5.5     Pituitary Hormone Deficiency(Ies)

Suppression of anterior pituitary hormones may occur on SIGNIFOR LAR. Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy. If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.

6     Adverse Reactions

  • Clinically significant adverse reactions that appear in other sections of the labeling include:
  • Hyperglycemia and Diabetes [see Warnings and Precautions (5.1)]Bradycardia and QT Prolongation [see Warnings and Precautions (5.2)]Liver Test Elevations [see Warnings and Precautions (5.3)]Cholelithiasis and Complications of Cholelithiasis [see Warnings and Precautions (5.4)]Pituitary Hormone Deficiency(ies) [see Warnings and Precautions (5.5)]

6.1     Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.
Drug-Naïve Patients With AcromegalyThe data described in Table 1 are derived from an active-controlled trial in patients with acromegaly naïve to previous drug therapy [see Clinical Studies (14.1)]. The data reflect exposure of 178 patients with acromegaly to SIGNIFOR LAR for a mean duration of 43 weeks. In the overall study population, 52% were female and the average age of patients was 45 years.
Table 1 presents common adverse reactions associated with SIGNIFOR LAR in this study. These adverse reactions were not present at baseline or, if present, worsened from baseline and occurred in at least 5% of patients treated with SIGNIFOR LAR.Table 1 – Adverse Reactions Occurring in Greater Than or Equal to 5% of Patients Exposed to SIGNIFOR LAR in Patients With Acromegaly Naïve to Drug Therapy*Diabetes mellitus includes the following PTs: diabetes mellitus and type 2 diabetes mellitus.**Sinus bradycardia includes the following PTs: bradycardia and sinus bradycardia.***Injection-site reaction related AEs includes the following PTs: injection-site pain, injection-site reaction, injection-site haematoma, injection-site pruritus, injection-site swelling, injection-site erythema.Adverse Reaction TypeSIGNIFOR LAR(40-60 mg)%N = 178Active Comparator%N = 180Hyperglycemia Related Adverse ReactionsHyperglycemia298Diabetes mellitus*264Blood glucose increased82Glycosylated hemoglobin increased 62Hypoglycemia57Gastrointestinal Related Adverse ReactionsDiarrhea3945Abdominal pain1822Nausea1422Abdominal distension1212Vomiting87Abdominal pain upper68Hepatobiliary Related Adverse ReactionsCholelithiasis2636Cardiac Related Adverse ReactionsSinus bradycardia**107Hypertension87Nervous System Related Adverse ReactionsHeadache1926Dizziness1011Skin Related Adverse ReactionsAlopecia1819Infections Related Adverse ReactionsNasopharyngitis1616Influenza84Upper respiratory tract infection73Cough58Laboratory Related Adverse ReactionsBlood creatine phosphokinase increased 1312Alanine aminotransferase increased84Aspartate aminotransferase increased64Lipase increased67Weight decreased54General and Injection-Site Related Adverse ReactionsFatigue1010Injection-site reaction***77Musculoskeletal and Connective Tissue Related Adverse ReactionsArthralgia1012Back pain811Pain in extremity74Blood Related Adverse ReactionsAnemia66Other notable adverse reactions which occurred with a frequency of 5% or less for SIGNIFOR LAR were: adrenal insufficiency (3%); glucose tolerance impaired (1%); QT-prolongation (4%); blood amylase increased (2%). Patients With Acromegaly Inadequately Controlled on Other Somatostatin Analogs at BaselineThe data described in Table 2 are derived from an active-controlled study in patients with acromegaly inadequately controlled at baseline on other somatostatin analogs [see Clinical Studies (14.2)]. These data reflect exposure of 63 and 62 patients to SIGNIFOR LAR 40 mg and 60 mg, respectively, for a mean duration of 24 weeks. In the overall study population, 56% were female and the average age of patients was 45 years.
Table 2 presents common adverse reactions associated with SIGNIFOR LAR in this study. These common adverse reactions were not present at baseline, or if present, worsened from baseline and occurred in at least 5% of patients treated with SIGNIFOR LAR.
Table 2 – Adverse Reactions Occurring in Greater Than or Equal to 5% of Patients Exposed to SIGNIFOR LAR in Patients With Acromegaly Previously Treated With Other Somatostatin Analogs*Diabetes mellitus includes the following PTs: diabetes mellitus and type 2 diabetes mellitus.Adverse Drug ReactionsSIGNIFOR LAR 40 mg%N = 63SIGNIFOR LAR 60 mg%N = 62Active Comparators%N = 66Hyperglycemia Related Adverse ReactionsHyperglycemia333014Diabetes mellitus*21319Blood glucose increased570Hypoglycemia370Gastrointestinal Related Adverse ReactionsDiarrhea16195Abdominal pain883Nausea373Hepatobiliary Related Adverse ReactionsCholelithiasis101314Cardiac Related Adverse ReactionsAtrioventricular block first degree600Nervous System Related Adverse ReactionsHeadache1435Dizziness823Skin and Subcutaneous Tissue Related Adverse ReactionsAlopecia270Infections Related Adverse ReactionsNasopharyngitis6113Blood Related Adverse ReactionsAnemia633Other notable adverse reactions which occurred with a frequency of 5% or less in the SIGNIFOR LAR 40 mg, SIGNIFOR LAR 60 mg arm, respectively, were adrenal insufficiency (2% and 0%) and glucose tolerance impaired (3% and 5%).
Patients With Cushing’s DiseaseThe data described in Table 3 are derived from a randomized clinical study in 150 patients with Cushing’s disease [see Clinical Studies (14.3)]. These data reflect exposure of 74 and 76 patients to SIGNIFOR LAR at a starting dose of 10 mg and 30 mg once every 28 days, respectively, for a mean duration of 68 weeks. In the overall study population, 79% of patients were female and the average age was 39 years at study entry.Table 3 presents common adverse reactions which were not present at baseline or, if present, worsened from baseline and occurred in at least 5% of patients treated with SIGNIFOR LAR.Table 3 – Adverse Reactions Occurring in Greater Than or Equal to 5% of Patients Exposed to SIGNIFOR LAR in Patients With Cushing’s Disease*Diabetes mellitus consists of the two terms: diabetes mellitus and type 2 diabetes mellitus.**Abdominal pain includes the term abdominal pain upper.***Sinus bradycardia includes the term bradycardia.****Fatigue includes the term asthenia.Adverse ReactionsOverall%N = 150Endocrine Related Adverse ReactionsAdrenal insufficiency7Blood cortisol decreased5Hyperglycemia Related Adverse ReactionsHyperglycemia47Diabetes mellitus*27Hypoglycemia15Blood glucose increased9Glycosylated hemoglobin (HbA1C) increased5Gastrointestinal Related Adverse ReactionsDiarrhea39Nausea21Abdominal pain**23Constipation7Abdominal distension5Flatulence5Vomiting5Hepatobiliary Related Adverse ReactionsCholelithiasis33Gamma-glutamyltransferase increased9Alanine aminotransferase increased7Cardiac Related Adverse ReactionsHypertension15Hypotension6Sinus bradycardia***5General Related Adverse ReactionsFatigue****27Edema peripheral14Musculoskeletal and Connective Tissue Related Adverse ReactionsBack pain11Arthralgia8Pain in extremity7Myalgia5Metabolism and Nutrition Related Adverse ReactionsDecreased appetite10Hyperuricemia7Hypercholesterolemia6Blood Related Adverse ReactionsAnemia5Other adverse reactions which occurred at a frequency less than 5% were cholestasis (4%), glucose tolerance impaired (3%), aspartate aminotransferase increased (3%), vomiting (3%), lipase increased (3%), injection-site reactions (2%), ECG QT prolonged (1%), cholecystitis (1%), amylase increased (1%), and prothrombin time prolonged (1%).HyperglycemiaThe average fasting plasma glucose levels in patients with acromegaly naïve to drug therapy study [see Clinical Studies (14.1)] across visits is shown in Figure 2 below.
Figure 2. Mean Fasting Plasma Glucose (mg/dL) By Visit in the Study of Patients With Acromegaly Naïve to Drug Therapy**Numbers of patients with a glucose value at the given timepoint in the SIGNIFOR LAR/Active comparator arms are displayed as xxx/xxx on the x axis.Pancreatic Enzyme Elevation and PancreatitisAsymptomatic elevations in lipase and alpha amylase were observed in 30% and 20% of patients receiving SIGNIFOR LAR in the drug naïve study in acromegaly, and in 1% and 3% of patients receiving SIGNIFOR LAR in the study of acromegaly patients previously treated. In the drug-naïve study, 2 acromegaly patients receiving SIGNIFOR LAR developed pancreatitis. In the Cushing’s disease study, increased lipase was observed in 4% of patients, and 1 patient developed pancreatitis. Pancreatitis is a potential adverse reaction associated with the use of SIGNIFOR LAR due to the association between cholelithiasis and acute pancreatitis.

6.2     Postmarketing Experience

  • Additional adverse reactions have been identified during postapproval use of SIGNIFOR LAR. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Cholelithiasis resulting in complications, including cholecystitis and cholangitis, which have sometimes required cholecystectomy

7.1     Effect Of Other Drugs On Signifor Lar

Drugs that Prolong QT
Coadministration of drugs that prolong the QT interval with SIGNIFOR LAR may have additive effects on the prolongation of the QT interval. Monitoring effects on the QT interval at 21 days is recommended [see Warnings and Precautions (5.2)].

7.2     Effect Of Signifor Lar On Other Drugs

CyclosporineConcomitant administration of cyclosporine with SIGNIFOR LAR may decrease the relative bioavailability of cyclosporine and, therefore, dose adjustment of cyclosporine to maintain therapeutic levels may be necessary.BromocriptineCoadministration of SIGNIFOR LAR with bromocriptine may increase the blood levels of bromocriptine. Dose reduction of bromocriptine may be necessary.

8.1     Pregnancy

Risk SummaryThe limited data with SIGNIFOR LAR in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. In embryo-fetal development studies in rabbits, findings indicating a developmental delay were observed with subcutaneous administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.DataAnimal DataIn embryo-fetal development studies in rats given 1 mg/kg/day, 5 mg/kg/day, and 10 mg/kg/day subcutaneously throughout organogenesis, maternal toxicity was observed at all doses, including the lowest dose tested which had exposures 12 times higher than that at the maximum therapeutic dose based on area under the curve (AUC) comparisons across species. An increased incidence of early/total resorptions and malrotated limbs was observed in rats at 10 mg/kg/day. At 10 mg/kg/day in rats, the maternal systemic exposure (AUC) was 42179 ng*hr/mL, approximately 106 times the exposure in humans at the highest recommended dose of 60 mg SIGNIFOR LAR administered as an intramuscular injection once every 4 weeks.In embryo-fetal development studies in rabbits given 0.05 mg/kg/day, 1 mg/kg/day, and 5 mg/kg/day subcutaneously through organogenesis, maternal toxicity was observed at 1 mg/kg/day, at a maternal systemic exposure (AUC) of 1906 ng*hr/mL, approximately 5 times higher than the maximum human therapeutic exposure. An increased incidence of unossified forepaw phalanx, indicative of a developmental retardation, was observed in rabbits at 0.05 mg/kg/day, with maternal systemic exposures less than the systemic exposure in humans at the highest recommended dose.In pre- and post-natal developmental studies in rats given subcutaneous doses of 2 mg/kg/day, 5 mg/kg/day, and 10 mg/kg/day during gestation through lactation and weaning, maternal toxicity was observed at all doses including the lowest dose (9 times higher than the maximum therapeutic dose based on surface area comparisons across species). Retardation of physiological growth, attributed to GH inhibition was observed at 2 mg/kg/day during a pre- and post-natal study in rats. After weaning, body weight gains in the rat pups (F1 generation) exposed to pasireotide were comparable to controls, showing reversibility of this developmental delay.

8.2     Lactation

Risk SummaryThere is no information available on the presence of SIGNIFOR LAR in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Studies show that pasireotide administered subcutaneously passes into the milk of lactating rats; however, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SIGNIFOR LAR, and any potential adverse effects on the breastfed child from SIGNIFOR LAR or from the underlying maternal condition.DataAvailable data in animals have shown excretion of pasireotide in milk. After a single 1 mg/kg [14C]-pasireotide subcutaneous dose to lactating rats, the transfer of radioactivity into milk was observed. The overall milk:plasma (M/P) exposure ratio of total radioactivity was 0.28, based on AUC0-∞ values.

8.3     Females And Males Of Reproductive Potential

Discuss the potential for unintended pregnancy with premenopausal women as the therapeutic benefits of a reduction in GH levels and normalization of IGF-1 in acromegalic females treated with pasireotide may lead to improved fertility.Similarly, the therapeutic benefits of a reduction or normalization of serum cortisol levels in female patients with Cushing’s disease treated with pasireotide may also lead to improved fertility.

8.4     Pediatric Use

Safety and effectiveness of SIGNIFOR LAR have not been established in pediatric patients.

8.5     Geriatric Use

Clinical studies of SIGNIFOR LAR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6     Hepatic Impairment

Dose adjustment is not required in patients with mild impaired hepatic function (Child-Pugh A), but is required for patients with moderately impaired hepatic function (Child-Pugh B). The safety and efficacy of SIGNIFOR LAR have not been established in patients with severe hepatic impairment (Child-Pugh C). No dosage recommendation can be given for patients with severe hepatic impairment (Child-Pugh C) [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].

8.7     Renal Impairment

Clinical studies of SIGNIFOR LAR in patients with renal impairment have not been conducted. On the basis of studies with pasireotide given subcutaneously, dosage adjustment is not needed in patients with renal impairment [see Clinical Pharmacology (12.3)].

10     Overdosage

In the event of overdosage, it is recommended that appropriate supportive treatment be initiated, as dictated by the patient’s clinical status, until resolution of the symptoms.
Up-to-date information about the treatment of overdose can be obtained from a certified Regional Poison Center. In the event of an overdose, contact the National Capital Poison Center at 1-800-222-1222 or www.poison.org.

11     Description

SIGNIFOR LAR (pasireotide) for injectable suspension is a long-acting release form of pasireotide pamoate, as powder to be suspended in the provided diluent immediately prior to intramuscular injection. SIGNIFOR LAR contains pasireotide, a somatostatin analog in the form of pasireotide pamoate (pamoic acid salt). Pasireotide is a cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Pasireotide pamoate has a chemical name of (2-Aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester pamoic acid salt.
The molecular formula of pasireotide pamoate is C58H66N10O9 • C23H16O6 and the molecular weight is 1435.58 g/mol. The structural formula is:
The drug product consists of pasireotide pamoate uniformly distributed within microspheres which are made of biodegradable copolymers of poly (D,L-lactide-co-glycolide) acids (PLGA).SIGNIFOR LAR is available in a vial containing the sterile pasireotide pamoate, PLGA microspheres powder, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg to be reconstituted with the provided 2 mL sterile diluent.Each vial contains:*corresponds to 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg of pasireotide base, respectively.10 mg20 mg30 mg40 mg60 mgPasireotide pamoate13.71 mg*
27.42 mg*
41.13 mg*
54.84 mg*
82.26 mg*
Poly(D,L-lactide-co-glycolide) [50-60:40-50] 13.15 mg26.29 mg39.44 mg52.58 mg78.87 mgPoly(D,L-lactide-co-glycolide) [50:50]13.15 mg26.29 mg39.44 mg52.58 mg78.87 mgEach diluent prefilled syringe contains:
Mannitol90 mgCarboxymethylcellulose sodium14 mgPoloxamer 1884 mgWater for injectionsadd to 2 mL

12.1     Mechanism Of Action

SIGNIFOR LAR is an injectable cyclohexapeptide, somatostatin analog. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). There are 5 known human somatostatin receptor subtypes: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogs bind to SSTRs with different potencies. Pasireotide binds with high affinity to 4 of the 5 SSTRs (see Table 4).Table 4 – Binding Affinities of Somatostatin (SRIF-14) and Pasireotide to the Five Human SSTR Subtypes (SSTR 1-5)Results are the mean + SEM of IC50 values expressed as nmol/l (nM).CompoundSSTR1SSTR2SSTR3SSTR4SSTR5Somatostatin (SRIF-14)0.93 ± 0.120.15 ± 0.020.56 ± 0.171.5 ± 0.40.29 ± 0.04Pasireotide9.3 ± 0.11.0 ± 0.11.5 ± 0.3> 1000.16 ± 0.01

12.2     Pharmacodynamics

Somatostatin receptors are expressed in many tissues including neuroendocrine tumors (e.g., growth hormone or adrenocorticotropic hormone secreting pituitary adenomas).AcromegalyPasireotide binds to SSTR2 and SSTR5 subtype receptors which may be relevant for inhibition of GH secretion. In vivo studies show that SIGNIFOR LAR lowers GH and IGF-1 levels in patients with acromegaly.Cushing’s DiseaseCorticotroph tumor cells from Cushing’s disease patients frequently over-express SSTR5 whereas the other receptor subtypes are often not expressed or are expressed at lower levels. Pasireotide binds and activates the SSTRs resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion.Cardiac ElectrophysiologyIndividually corrected QT (QTcI) interval was evaluated in a randomized, blinded, crossover study in healthy subjects investigating pasireotide subcutaneous doses of 0.6 mg and 1.95 mg twice daily, respectively. The maximum mean (95% upper confidence bound) placebo-subtracted QTcI change from baseline was 12.7 (14.7) ms and 16.6 (18.6) ms, respectively. Both pasireotide doses decreased heart rate, with a maximum mean (95% lower confidence bound) placebo-subtracted change from baseline of -10.9 (-11.9) beats per minute (bpm) observed at 1.5 hours for pasireotide 0.6 mg twice daily, and -15.2 (-16.5) bpm at 0.5 hours for pasireotide 1.95 mg twice daily.
The predicted pasireotide peak concentration (25.8 ng/mL) following SIGNIFOR LAR 60-mg dose in acromegaly patients is similar to the observed peak concentration (24.3 mg/mL) of the subcutaneous SIGNIFOR 0.6 mg twice daily dose and below the observed peak concentration (80.6 ng/mL) of the subcutaneous SIGNIFOR 1.95 mg twice daily dose. The predicted pasireotide peak concentration for the SIGNIFOR LAR dose of 40 mg in Cushing’s disease patients is 14 ng/mL.

12.3     Pharmacokinetics

Pasireotide for intramuscular use is formulated as microspheres for long-acting release. After a single injection, the plasma pasireotide concentration shows an initial burst release on the injection day, followed by a dip from Day 2 to Day 7, then a slow increase to the maximum concentration around Day 21, and a slow declining phase over the next weeks, concomitant with the terminal degradation phase of the polymer matrix of the dosage form.Absorption and DistributionNo studies have been conducted to evaluate the absolute bioavailability of pasireotide in humans. Food effect is unlikely to occur since SIGNIFOR LAR is administered via a parenteral route.
In healthy volunteers, pasireotide administered as SIGNIFOR LAR is widely distributed with large apparent volume of distribution (Vz/F > 100 L). Distribution between blood and plasma is concentration-independent and shows that pasireotide is primarily located in the plasma (91%). Plasma protein binding is moderate (88%) and independent of concentration.
Pasireotide has low passive permeability and is likely to be a substrate of P-glycoprotein (P-gp), but the impact of P-gp on the ADME (absorption, distribution, metabolism, excretion) of pasireotide is expected to be low. In clinical testing in healthy volunteers, P-gp inhibition did not affect the rate or extent of pasireotide availability [see Drug Interactions (7.1)]. At therapeutic dose levels, pasireotide is not expected to be a substrate of BCRP (breast cancer resistance protein), OCT1 (organic cation transporter 1), or OATP (organic anion-transporting polypeptides) 1B1, 1B3, or 2B1.
EliminationMetabolism and ExcretionPasireotide was shown to be highly metabolically stable in human liver and kidney microsomes. In healthy volunteers, pasireotide in its unchanged form is the predominant form found in plasma, urine and feces. Somatropin may increase CYP450 enzymes and, therefore, suppression of GH secretion by somatostatin analogs including pasireotide may decrease the metabolic clearance of compounds metabolized by CYP450 enzymes.
Pasireotide is eliminated mainly via hepatic clearance (biliary excretion) with a small contribution of the renal route. In a human ADME study with subcutaneous SIGNIFOR with a single dose 0.6 mg, 55.9 ± 6.63% of the radioactivity dose was recovered over the first 10 days post dosing, including 48.3 ± 8.16% of the radioactivity in feces and 7.63 ± 2.03% in urine.The apparent clearance (CL/F) of SIGNIFOR LAR in healthy volunteers is on average 4.5-8.5 L/hour.
Steady-State PharmacokineticsPK steady-state for SIGNIFOR LAR is achieved after 3 monthly doses. Following multiple intramuscular doses every 4 weeks (every 28 days), SIGNIFOR LAR demonstrates approximately dose-proportional PK exposures (steady-state trough; Ctrough, ss) in the dose range of 10 mg to 60 mg every 4 weeks.
Special PopulationsPopulation PK analyses of SIGNIFOR LAR suggest that race, gender, and body weight do not have clinically relevant influence on circulating levels of pasireotide. No dose adjustment is required for demographics.
Pediatric PatientsNo studies have been performed in pediatric patients [see Use in Specific Populations (8.4)].Geriatric PatientsAge is not a significant covariate in the population PK analysis. Therefore age is not expected to significantly impact circulating levels of pasireotide.
Efficacy and safety data on patients older than 65 years are limited [see Use in Specific Populations (8.5)].
Hepatic ImpairmentIn a clinical study with a single subcutaneous dose of 600 µg pasireotide in subjects with impaired hepatic function (Child-Pugh A, B and C), subjects with moderate and severe hepatic impairment (Child-Pugh B and C) showed significantly higher exposures than subjects with normal hepatic function. Upon comparing with the control group, AUCinf was increased by 12%, 56%, and 42%; and Cmax was increased by 3%, 46%, and 33% respectively, in the mild, moderate, and severe hepatic impairment groups [see Use in Specific Populations (8.6), Dosage and Administration (2.5)].
Renal ImpairmentClinical studies have not been performed in patients with renal impairment. However, renal clearance has a minor contribution to the elimination of pasireotide in humans. Renal function (creatinine clearance and estimated glomerular filtration rate) is not a covariate in the population PK analysis. Therefore, renal function is not expected to significantly impact the circulating levels of pasireotide [see Use in Specific Populations (8.7)].

13.1     Carcinogenesis, Mutagenesis, Impairment Of Fertility

CarcinogenesisA lifetime carcinogenicity study was conducted in rats and transgenic mice. Rats were given daily subcutaneous doses of pasireotide at 0.01 mg/kg/day, 0.05 mg/kg/day, and 0.3 mg/kg/day for 104 weeks. There were no drug-related tumors in rats at exposures up to 5-times higher than the maximum recommended clinical exposure of the pasireotide LAR 60 mg dose. Mice were given subcutaneous doses of pasireotide at 0.5 mg/kg/day, 1 mg/kg/day, and 2.5 mg/kg/day for 26 weeks and did not identify any carcinogenic potential.MutagenesisPasireotide was not genotoxic in a battery of in vitro assays (Ames mutation test in Salmonella and Escherichia coli and mutation test in human peripheral lymphocytes). Pasireotide was not genotoxic in an in vivo rat bone marrow nucleus test.Impairment of FertilitySubcutaneous dosing at 0.1 mg/kg/day before mating and continuing into gestation in rats at exposures less than the human clinical exposure based on body surface area comparisons across species resulted in statistically significant increased implantation loss and decreased viable fetuses, corpora lutea, and implantation sites. Abnormal cycles or acyclicity were observed at 1 mg/kg/day (4-fold higher than the maximum therapeutic exposure of pasireotide LAR based on surface area, comparisons across species).

14.1     Drug-Naïve Patients With Acromegaly

A multicenter, randomized, double-blind study was conducted to assess the safety and efficacy of SIGNIFOR LAR in patients with active acromegaly. A total of 358 patients naïve to drugs used to treat acromegaly were randomized in a 1:1 ratio to SIGNIFOR LAR or another somatostatin analog active comparator. Randomization was stratified based on previous pituitary surgical status (e.g., at least 1 prior pituitary surgery versus no prior pituitary surgery).In the overall study population, 52% were female and the average age of patients was 45 years. Sixty percent of patients were Caucasian, 23% Asian, 12% Other, 3% American Indian, and 2% were Black. Forty-two percent of patients had previous pituitary surgery, and 1 patient had a history of pituitary radiation therapy. Median time between diagnosis and trial participation was 6 months. Median GH was 8.8 mcg/L (range: 0.8-200 mcg/L) and 10.1 mcg/L (range: 0.6–169.6 mcg/L) for SIGNIFOR LAR and active comparator, respectively at baseline. Median standardized IGF-1, defined as IGF-1 value divided by the ULN (i.e., fold above the ULN), was 2.9 (range: 0.9–6.9) and 2.9 (range: 0.8–7.3), for SIGNIFOR LAR and active comparator, respectively, at baseline.
The starting dose of SIGNIFOR LAR was 40 mg. Dose increase was allowed in both arms, at the discretion of investigators, after 3 and 6 months of treatment if mean GH was greater than or equal to 2.5 mcg/L and/or IGF-1 was greater than the ULN for age and sex. The maximum allowed dose for SIGNIFOR LAR was 60 mg. The maximum dose of the active comparator was not used in this trial because the trial was multi-national and the maximum dose approved in the US was not approved in all participating countries.
The efficacy endpoint was the proportion of patients with a mean GH level less than 2.5 mcg/L and a normal IGF-1 levels at month 12 (age- and sex-adjusted) (see Table 5, Figure 3, and Figure 4). The proportion of patients achieving this level of control was 31.3% and 19.2% for SIGNIFOR LAR and active comparator, respectively. The changes in mean GH and IGF-1 levels by study visits in subjects with a measurement at these visits (observed cases) are shown in Figures 3 and 4.
Table 5 – Results at Month 12 in Drug-Naïve Patients Study*Primary endpoint [patients with IGF-1< lower limit of normal (LLN) were not considered as “responders”].ULN = Upper limit of normal.**p-value < 0.01 for treatment difference.&The maximum dose approved for use in the United States was not used in this trial but the majority of patients were receiving the dose most commonly used in the United States to treat acromegaly.
SIGNIFOR LAR(40-60 mg)%
N = 176Active Comparator&%
N = 182GH < 2.5 mcg/L and normalized IGF-1*31.3%**19.2%GH < 2.5 mcg/L and IGF-1 ≤ ULN35.8%20.9%Normalized IGF-138.6%**23.6%GH < 2.5 mcg/L48.3%51.6%Figure 3. Mean GH (mcg/L) Levels By Visit in Drug Naïve Patient Study**Numbers of patients with a GH value at the given timepoint for SIGNIFOR LAR/Active comparator arm are displayed as xxx/xxx on the x-axis.Figure 4. Mean Standardized IGF-1 Levels* By Visit in Drug Naïve Patient Study** **Numbers of patients with an IGF-1 value at the given timepoint for SIGNIFOR LAR/Active comparator arm are displayed as xxx/xxx on the x axis.
Biochemical control was achieved by Month 3 in 30.1% of patients in the SIGNIFOR LAR arm. Ninety-eight percent of patients treated with SIGNIFOR LAR had either a reduction or no change in tumor volume from baseline assessed by MRI at Month 12. The median (range) change in tumor volume was a reduction of 39.8% (-97.6% to 16.9%).
Additionally, ring size and acromegaly symptoms score (i.e., headache, fatigue, perspiration, paresthesia, and osteoarthralgia) were followed. At Month 12, reductions in ring size and in symptom severity scores in both treatment groups compared to baseline were noted.

14.2     Patients With Acromegaly Inadequately Controlled On Other Somatostatin Analogs

A multicenter, randomized, 3-arm study was conducted in patients with acromegaly inadequately controlled on somatostatin analogs. Patients were randomized to double-blind SIGNIFOR LAR 40 mg (n = 65) or SIGNIFOR LAR 60 mg (n = 65) or to continued open-label pretrial somatostatin analog therapies at maximal or near maximal doses (n = 68). A total of 181 patients completed the 6-month trial.Inadequate control was defined as a GH concentration of greater than 2.5 mcg/L (i.e., mean of 5 samples over 2 hours) and a sex- and age-adjusted IGF-1 level greater than 1.3 times the upper limit of normal. Patients were required to have been treated with other somatostatin analogs for at least 6 months prior to randomization. Note that the maximum dose for one of the active comparators approved for use in the United States was not used in this multinational trial; approximately 75% of the population in the comparator group was receiving this active comparator.In the overall study population, 56% were female and the average age of patients was 45 years. Eighty-one percent of patients were Caucasian, 7% Other, 8% Black, 2% American Indian, and 2% Asian. The percentage of patients with previous pituitary surgery in the SIGNIFOR LAR 40 mg and 60 mg arms, and in the active control arm was 77%, 63%, and 60%, respectively. Three percent of patients in the SIGNIFOR LAR groups and 7% of patients in the active control arm had prior radiation therapy. Median (range) time from diagnosis to participation in this trial was 50 (10–337) months, 55 (8–357) months, and 54 (8–357) months in the SIGNIFOR LAR 40 mg, 60 mg and the pretrial therapy arms, respectively. At baseline, median (range) GH was 7.1 (1.0–200) mcg/L, 5.3 (1.4–113.8) mcg/L and 6.1 (1.0–92.4) mcg/L in the SIGNIFOR LAR 40 mg, 60 mg and the pretrial therapy arms, respectively. Baseline median standardized IGF-1 (defined as IGF-1 value divided by the ULN) values were 2.3, 2.6 and 2.9 in the SIGNIFOR LAR 40 mg, 60 mg and the pretrial therapy arms, respectively.The efficacy endpoint was the proportion of patients with a mean GH level less than 2.5 mcg/L and normal IGF-1 levels at week 24. The primary analysis compared SIGNIFOR LAR 60 mg and 40 mg to continued pretrial therapy (i.e., no change in treatment). The proportion of patients achieving biochemical control was 15.4% and 20.0% for SIGNIFOR LAR 40 mg and 60 mg, respectively, at 6 months.Biochemical control was achieved by Month 3 in 15.4% and 18.5% of patients in the SIGNIFOR LAR 40 mg and 60 mg arms, respectively.Table 6 – Results at 6 Months in Inadequately Controlled Patient Study*Primary endpoint (patients with IGF-1 < lower limit of normal (LLN) were not considered as “responders”).&For one of the active comparators, the maximum dose approved for use in the United States was not used in this trial but the majority of patients were receiving the dose most commonly used in the United States to treat acromegaly.SIGNIFOR LAR 40 mg%N = 65SIGNIFOR LAR 60 mg%N = 65ContinuedPre-Trial TherapyControl Arm&%N = 68GH < 2.5 mcg/L and normalized IGF-1*15.4%20.0%0%Normalization of IGF-124.6%26.2%0%GH < 2.5 mcg/L35.4%43.1%13.2%Eighty-one percent and 70% of patients treated with SIGNIFOR LAR 40 mg and 60 mg, respectively, had either a reduction or no change in tumor volume from baseline assessed by MRI at Month 6. The median (range) change in tumor volume was a reduction of -10.4% (-74.5% to 19.4%) and -6.3% (-66.7% to 14.5%) from baseline for SIGNIFOR LAR 40 mg and 60 mg, respectively.

14.3     Patients With Cushing’S Disease

A Phase 3, randomized, double-blind, multicenter study was conducted to evaluate the safety and efficacy of two dose regimens of SIGNIFOR LAR over a 12-month treatment period in patients with persistent or recurrent Cushing’s disease, or de novo patients who were not considered candidates for pituitary surgery.The study enrolled 150 patients with a screening mean urinary free cortisol level (mUFC) ≥ 1.5 and ≤ 5 x ULN, who were randomized in a 1:1 ratio to receive a SIGNIFOR LAR starting dose of either 10 mg intramuscularly once every 28 days or 30 mg intramuscularly once every 28 days. Randomization was stratified by values of mUFC at screening (1.5 to < 2 x ULN versus 2 to 5 x ULN, respectively).After four months of treatment, patients who had a mUFC ≤ 1.5 x ULN continued on the blinded dose to which they were randomized. Patients with a mUFC > 1.5 x ULN at Month 4 had their doses increased in a blinded manner from 10 mg to 30 mg, or from 30 mg to 40 mg, provided there were no tolerability concerns. Additional dose increases were allowed at Month 7 and Month 9 (by one dose level if the mUFC was > 1 x ULN).Dose reduction by one dose level for tolerability was allowed in a blinded fashion for the first seven months, with a minimum dose level of 5 mg. After the first seven months, blinded down titration of more than one dose level was allowed at any month.After twelve months of treatment (core phase), patients had the option to enter an extension to continue to receive SIGNIFOR LAR if they benefited from treatment.The primary efficacy endpoint was the proportion of patients in each arm who were mUFC responders (mUFC ≤ ULN) after seven months of treatment, with or without up-titration at Month 4. The key secondary endpoint was the proportion of patients in each arm who were mUFC responders after seven months of treatment and who did not up-titrate the dose prior to Month 7. The pre-specified boundary of the lower limit of the 95% confidence interval (CI) for efficacy for both the primary and key secondary endpoints was 15%. Patients with missing mUFC assessment at Month 7 were classified as non-responders. Other secondary endpoints included changes from baseline in 24-hour UFC, plasma ACTH, and serum cortisol levels. All analyses were conducted based on the randomized dose groups.Baseline demographics and disease history were well balanced between the two randomized dose groups and consistent with the epidemiology of the disease. The mean age of patients was approximately 38.5 years with a predominance of female patients (78.7%). The majority of the patients had persistent or recurrent Cushing’s disease (82.0%). The median value of the baseline 24-hour mUFC for all patients was 396.9 nmol/24 hours (ULN: 166.5 nmol/24 hours). About three-quarters of all randomized patients completed seven months of treatment, and about two-thirds of all randomized patients completed twelve months of treatment.The study met the primary efficacy objective for both dose groups. Patients were considered responders if they remained on treatment until at least Month 7 and achieved a Month 7 mUFC ≤ 1 x ULN, regardless of up-titration at Month 4. The proportion of patients with mUFC response at Month 7 was 39.2% (95% CI: 28.0, 51.2) in the 10 mg arm and 40.8% (95% CI: 29.7, 52.7) in the 30 mg arm. The responder rate at Month 12 was 35.1% (26/74) and 25.0% (19/76) in the 10 mg and 30 mg starting dose groups, respectively.Table 7 – Response Rates at Month 7 per Randomized Dose Group and According to Screening mUFC - There were 17 (23.0%) patients in 10 mg arm and 9 (11.8%) in the 30 mg arm with missing value mUFC assessments at Month 7 who were classified as non-responders.
Pasireotide LAR10 mg Every 28 DaysPasireotide LAR30 mg Every 28 DaysScreening mUFC categoryn/N (%)95% CIn/N (%)95% CIAll patients29/74 (39.2)(28.0, 51.2)31/76 (40.8)(29.7, 52.7)≥ 1.5 x ULN to < 2 x ULN11/25 (44.0)(24.4, 65.1)13/25 (52.0)(31.3, 72.2)≥ 2 x ULN to ≤ 5 x ULN18/49 (36.7)(23.4, 51.7)18/51 (35.3)(22.4, 49.9)The study met the key secondary efficacy objective for both dose groups. At Month 4, 31/74 (41.9%) and 28/76 (36.8%) patients were up-titrated in the pasireotide LAR 10 mg and 30 mg arms, respectively. When all patients who up-titrated prior to Month 7 were counted as non-responders, Month 7 mUFC response was observed in 25.7% (95% CI: 16.2 to 37.2) and 31.6% (95% CI: 21.4 to 43.3) of patients randomized to pasireotide LAR at a starting dose of 10 mg once every 28 days and 30 mg once every 28 days, respectively.A secondary efficacy analysis was conducted for the combined proportion of patients who attained mUFC ≤ ULN (controlled) or had at least 50% reduction in mUFC (partially controlled) in the core phase of the study. The combined rate of controlled or partially controlled responders at Month 7 constituted 44.6% and 53.9% of patients randomized to the 10 mg and 30 mg dose groups, respectively (Table 8).Table 8 – Response Rates at Month 7 per Randomized Dose Group - Supportive Efficacy Analysis Response CategoryPasireotide LAR10 mg Every 28 Days(N = 74)n (%)Pasireotide LAR30 mg Every 28 Days(N = 76)n (%)Controlled (mUFC ≤ ULN)29 (39.2%)31 (40.8%)Partially controlled (≥ 50% reduction in mUFC) 4 (5.4%)10 (13.2%)Combined33 (44.6%)41 (53.9%)Decreases in median mUFC levels at Month 7 compared to baseline, as measured by overall percentage of reduction, are shown in Table 9. Reductions in serum cortisol and plasma ACTH levels were also observed at Months 7 and 12 for each dose group.Table 9 – Median Percentage Change from Baseline in Mean Urinary Free Cortisol (mUFC) at Month 7 by Randomized Dose GroupNote: Median % change from baseline in mUFC at Month 7 are calculated by imputing missing values with the worst observed % change in mUFC at Month 7 within each treatment group.Pasireotide LAR 10 mg Every 28 Days
% change
Pasireotide LAR 30 mg Every 28 Days
% change
mUFC levels (nmol/24hr)
Baseline
NMean (SD)Median74462.6 (256.41)409.876477.1 (331.75)371.6Median change in mUFC (% from baseline)Month 7-41.3%-41.4%

16.1     How Supplied

  • SIGNIFOR LAR for injectable suspension is supplied in a single-use kit containing the following:One 6-mL brownish glass vial with a grey rubber stopper of SIGNIFOR LAR containing slightly yellow to yellow powder with a flip-off capOne 3-mL glass barrel/grey rubber stopper prefilled syringe containing 2 mL of clear, colorless to slightly yellow/brown diluent solution for reconstitutionOne sterile 20G x 1.5” stainless steel, polypropylene safety injection needleOne vial adapter made of polycarbonate for drug product reconstitutionSIGNIFOR LAR kits are available in the following strengths:SIGNIFOR LAR KitFinal Concentration When Reconstituted
  • (total product strength per total volume)
  • Final Concentration When Reconstituted(per mL)
  • Flip-off Cap ColorNDC10 mg10 mg/2 mL5 mg/mLBrown0078-0748-8120 mg20 mg/2 mL10 mg/mLGray0078-0641-8130 mg30 mg/2 mL15 mg/mLLilac0078-0741-8140 mg40 mg/2 mL20 mg/mLRed0078-0642-8160 mg60 mg/2 mL30 mg/mLOrange0078-0643-81

16.2     Storage And Handling

Store at 2°C to 8°C (36°F-46°F). Do not freeze.SIGNIFOR LAR should be stored at refrigerated temperatures between 2°C to 8°C (36°F-46°F) until the time of use. SIGNIFOR LAR drug product kit should remain at room temperature for a minimum of 30 minutes before reconstitution, but should not exceed 24 hours at room temperature. However, after preparation of the drug suspension, it must be administered immediately.

17     Patient Counseling Information

  • Advise the patient to read the FDA-approved patient labeling (Patient Information).Instruct patients on the importance of adhering to their return visit schedule.Advise patients that SIGNIFOR LAR should only be administered by a trained healthcare professional.Hyperglycemia and DiabetesAdvise patients to assess fasting plasma glucose and HbA1c prior to starting treatment with SIGNIFOR LAR and advise patients to consistently monitor blood glucose levels, particularly after the start of treatment or after dose changes, so that appropriate action can be taken [see Warnings and Precautions (5.1)].Bradycardia and QT ProlongationAdvise patients that an ECG will be taken before treatment and periodically thereafter. Advise patients with cardiac disease and with risk factors for QT prolongation and bradycardia that adjustments in cardiac medications may be made and electrolyte disturbances may require correction [see Warnings and Precautions (5.2)].Liver Test ElevationsAdvise patients that liver function will be assessed prior to starting treatment with SIGNIFOR LAR and will be closely monitored for the first three months of treatment and thereafter as clinically indicated [see Warnings and Precautions (5.3)].Cholelithiasis and Complications of CholelithiasisInform patients that cholelithiasis and complications of cholelithiasis have been reported with the use of SIGNIFOR LAR [see Warnings and Precautions (5.4)].Advise patients to contact their healthcare provider if they experience signs or symptoms of gallstones (cholelithiasis) or complications of cholelithiasis (e.g., cholecystitis or cholangitis) [see Warnings and Precautions (5.4)].Advise patients that the gallbladder will be monitored by ultrasound periodically [see Warnings and Precautions (5.4)].Pituitary Hormone Deficiency(ies)Advise patients that monitoring of anterior pituitary function will be performed periodically [see Warnings and Precautions (5.5)].Distributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936
  • T2019-53

* Please review the disclaimer below.